Evidence map›Paper›PMID 34840720›Full record

ArticleInternational journal of hematologic oncology2021

A Phase I trial of talazoparib in patients with advanced hematologic malignancies.

Ajay K Gopal, Rakesh Popat, Ryan J Mattison, Tobias Menne, Adrian Bloor, Terry Gaymes, Asim Khwaja, Mark Juckett, Ying Chen, Matthew J Cotter and 1 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of hematologic oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01399840 (Phase 1, Two-arm, Open-label Study Of Once Daily, Oral Bmn 673 In Patients With Advanced Hematological Malignancies), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01399840 phase1completednot on this map

Phase 1, Two-arm, Open-label Study Of Once Daily, Oral Bmn 673 In Patients With Advanced Hematological Malignancies

TypeinterventionalSponsorPfizerRan2011 to 2014Enrolled33ConditionsAcute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Lymphocytic Leukemia, Mantle Cell LymphomaArmsBMN 673
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 2 countries.

Ajay K GopalDivision of Medical Oncology, Department of Medicine, University of Washington, Seattle, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.ORCID https://orcid.org/0000-0003-3023-6834
Rakesh PopatNational Institute for Health Research University College London Hospitals Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, UK.ORCID https://orcid.org/0000-0001-6553-4681
Ryan J MattisonCarbone Cancer Center, University of Wisconsin, Madison, WI, USA.ORCID https://orcid.org/0000-0001-8574-8365
Tobias MenneDepartment of Hematology, Freeman Hospital, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK.
Adrian BloorThe Christie NHS Foundation Trust, University of Manchester, Manchester, UK.
Terry GaymesDepartment of Biomolecular Science, Kingston University, London, UK.
Asim KhwajaUniversity College London Cancer Institute & University College London Hospitals NHS Foundation Trust, London, UK.ORCID https://orcid.org/0000-0002-6834-5625
Mark JuckettCarbone Cancer Center, University of Wisconsin, Madison, WI, USA.ORCID https://orcid.org/0000-0003-2074-5678
Ying ChenPfizer Inc., New York, NY, USA.
Matthew J CotterPfizer Inc., New York, NY, USA.
Ghulam J MuftiDepartment of Hematology, King's College London, King's College Hospital NHS Foundation Trust, London, UK.
Pfizer (United States) · USUniversity College London Hospitals NHS Foundation Trust · GBUniversity of Wisconsin–Madison · USKing's College London · GBKingston University · GBNewcastle upon Tyne Hospitals NHS Foundation Trust · GBUniversity of Manchester · GBUniversity of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThe objective of this study was to establish the maximum tolerated dose (MTD), safety, pharmacokinetics, and anti-leukemic activity of talazoparib. PATIENTS &

methodsThis Phase I, two-cohort, dose-escalation trial evaluated talazoparib monotherapy in advanced hematologic malignancies (cohort 1: acute myeloid leukemia/myelodysplastic syndrome; cohort 2: chronic lymphocytic leukemia/mantle cell lymphoma).

resultsThirty-three (cohort 1: n = 25; cohort 2: n = 8) patients received talazoparib (0.1-2.0 mg once daily). The MTD was exceeded at 2.0 mg/day in cohort 1 and at 0.9 mg/day in cohort 2. Grade ≥3 adverse events were primarily hematologic. Eighteen (54.5%) patients reported stable disease.

conclusionTalazoparib is relatively well tolerated in hematologic malignancies, with a similar MTD as in solid tumors, and shows preliminary anti leukemic activity.Clinical trial registration: NCT01399840 (ClinicalTrials.gov).

Indexed as

BRCA1/2 mutationsDNA damage responsehematologic malignancypoly(ADP-ribose) polymerase inhibitiontalazoparib

Identifiers

PMID34840720
PMCPMC8609999
OpenAlexW3202837993

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.